Your browser does not support JavaScript!
http://iet.metastore.ingenta.com
1887

Accounting for quiescent cells in tumour growth and cancer treatment

Accounting for quiescent cells in tumour growth and cancer treatment

For access to this article, please select a purchase option:

Buy article PDF
£12.50
(plus tax if applicable)
Buy Knowledge Pack
10 articles for £75.00
(plus taxes if applicable)

IET members benefit from discounts to all IET publications and free access to E&T Magazine. If you are an IET member, log in to your account and the discounts will automatically be applied.

Learn more about IET membership 

Recommend Title Publication to library

You must fill out fields marked with: *

Librarian details
Name:*
Email:*
Your details
Name:*
Email:*
Department:*
Why are you recommending this title?
Select reason:
 
 
 
 
 
IEE Proceedings - Systems Biology — Recommend this title to your library

Thank you

Your recommendation has been sent to your librarian.

A four-state cell-cycle model with explicit G1-phase representation, termed the quiescent-cell model (QCM), has been proposed to represent biologically the G1-phase specific effect of the chemotherapeutic tamoxifen. The QCM was used to model untreated and tamoxifen-treated tumour xenograft data from the literature with equivalent accuracy to previously developed tumour growth models. Open-loop analysis demonstrated that perturbations to the two newly introduced parameters, kG01 and kG10, significantly altered untreated tumour growth predictions. However, the sensitivity did not carry over to closed-loop simulations, where alterations to kD and kGS proved most significant in determining overall controller performance. Additional mismatch studies comparing controllers designed using the QCM to controllers designed with the Gompertz model and saturating-rate, cell-cycle model returned similar performance for a stepwise tumour reduction case study, but the quiescent-cell controller delivered a more aggressive treatment regimen. More importantly, the Gompertz and saturating-rate, cell-cycle controllers were unable to follow a reference trajectory when measurement updates were made biweekly, with both controllers returning tamoxifen dose schedules alternating between the maximum and minimum allowable dose.

References

    1. 1)
      • B.A. Conley , T.S. Ramsland , D.L. Sentz , S. Wu , D.M. Rosen , M. Wollman , J.L. Eiseman . Antitumour activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice. Cancer Chemother. Pharmacol. , 183 - 197
    2. 2)
      • Florian, J.A., Eiseman, J.L., Parker, R.S.: `A nonlinear model predictive control algorithm for breast cancer treatment', Proc. DYCOPS 7, 2004, Boston, MA, p. 1–12.
    3. 3)
      • G.S. Lee , K.S. Ryu , S.P. Kim , S.E. Namkoong , K.T. Han . Multiparametric flow cytometric analysis in a breast cancer cell line (MCF-7). J. Obstet. Gynaecol. Res. , 3 , 141 - 148
    4. 4)
    5. 5)
      • J.C. Panetta , J. Adam . A mathematical model of cycle-specific chemotherapy. Math. Comput. Model. , 2 , 67 - 82
    6. 6)
      • N.M. Lopes , E.G. Adams , B.K. Bhuyan . Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemothers Pharmacol. , 3 , 235 - 242
    7. 7)
      • M. Morari , N.L. Ricker . (1994) Model predictive control toolbox.
    8. 8)
      • F. Allgöwer , T.A. Badgwell , J.S. Qin , J.B. Rawlings , S.J. Wright . (1999) Nonlinear predictive control and moving horizon estimation – an introductory overview, advances in control – highlights of ECC '99.
    9. 9)
      • M.J. Ellis , S.M. Swain , B.A. Chabner , D.L. Longo . (2001) Steroid hormone therapies for cancer, Cancer chemotherapy and biotherapy: principles and practice.
    10. 10)
      • D.Z. D'Argenio , A. Schumitzky . (1997) ADAPT II users guide: Pharmacokinetic and pharmacodynamic systems analysis software, biomedical simulations resource.
    11. 11)
      • S.P. Robinson , S.M. Langan-Fahey , A.J. Delinda , V.C. Jordan . Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab. Dispos. , 1 , 36 - 43
    12. 12)
      • L. Norton . A Gompertzian model of human breast cancer growth. Cancer Res. , 7067 - 7071
    13. 13)
      • E.A. Martin , P. Carthew , I.N. White , R.T. Heydon , M. Gaskell , R.J. Mauthe , K.W. Turteltaub , L.L. Smith . Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. Carcinogenesis , 11 , 2209 - 2215
    14. 14)
      • Harrold, J.M., Eiseman, J.L., Zamboni, W.C., Parker, R.S.: `Modeling of toxicity effects and nonlinearities in pharmacokinetics of 9-nitrocamptothecin in mice', AIChE Annual Meeting, 2004, Austin, TX.
    15. 15)
      • M. Eslami . (1994) Theory of sensitivity in dynamic systems.
    16. 16)
    17. 17)
      • J.M. Slingerland , I.F. Tannock , I.F. Tannock , R.P. Hill , J. Morgan . (1998) Cell proliferation and cell death, The basic science of oncology.
    18. 18)
      • H. Akaike . A Bayesian extension of the minimal AIC procedures of autoregressive model fitting. Biometrika
    19. 19)
      • M. Morari , E. Zafirou . (1989) Robust process control.
    20. 20)
      • H. Shapiro . (2003) Practical flow cytometry.
    21. 21)
      • H. Minami . A point, a line, or an area? Which is the most important in the pharmacological analysis of cancer chemotherapy?. J. Clin. Oncol. , 3 , 405 - 406
    22. 22)
      • R. Martin , K.L. Teo . (1994) Optimal control of drug administration in cancer chemotherapy.
    23. 23)
      • C.H. Takimoto , S.G. Arbuck , B.A. Chabner , D.L. Longo . (2001) Topoisomerase I targeting agents: the camptothecins, Cancer chemotherapy & biology.
    24. 24)
      • (2005) Cancer facts & figures: 2005.
    25. 25)
      • M. Riesberg , C. Kasper , K.F. Reardon , T. Scheper . Flow cytometry in biotechnology. Appl. Microbiol. Biotechnol. , 350 - 360
http://iet.metastore.ingenta.com/content/journals/10.1049/ip-syb_20050041
Loading

Related content

content/journals/10.1049/ip-syb_20050041
pub_keyword,iet_inspecKeyword,pub_concept
6
6
Loading
This is a required field
Please enter a valid email address